ArticleNeurobiology of learning and memory2014
RGS9-2 modulates sensory and mood related symptoms of neuropathic pain.
Article in Neurobiology of learning and memory, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Molecular Regulatory Mechanisms of Mammary Gland Development: A Review.Animals : an open access journal from MDPI · 2025Review
- Sex-Specific Contrasting Role of BECLIN-1 Protein in Pain Hypersensitivity and Anxiety-Like Behaviors.eNeuro · 2025Article
- PMProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Tianeptine promotes lasting antiallodynic effects in a mouse model of neuropathic pain.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
- Macrophage regulator of G-protein signaling 12 contributes to inflammatory pain hypersensitivity.Annals of translational medicine · 2021Article
- Regulator of G-Protein Signaling (RGS) Protein Modulation of Opioid Receptor Signaling as a Potential Target for Pain Management.Frontiers in molecular neuroscience · 2020Review
- The Mesolimbic Dopamine System in Chronic Pain and Associated Affective Comorbidities.Biological psychiatry · 2020Review
- RGS4 Maintains Chronic Pain Symptoms in Rodent Models.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019Article
- Regulator of G-Protein Signaling 4 (RGS4) Controls Morphine Reward by Glutamate Receptor Activation in the Nucleus Accumbens of Mouse Brain.Molecules and cells · 2018Article
- Suppression of RGSz1 function optimizes the actions of opioid analgesics by mechanisms that involve the Wnt/β-catenin pathway.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Looking beyond the intervertebral disc: the need for behavioral assays in models of discogenic pain.Annals of the New York Academy of Sciences · 2017Review
- RGS9-2 Modulates Responses to Oxycodone in Pain-Free and Chronic Pain States.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Article
- Neuropathic pain promotes adaptive changes in gene expression in brain networks involved in stress and depression.Science signaling · 2017Article
- Reward Circuitry Plasticity in Pain Perception and Modulation.Frontiers in pharmacology · 2017Review
- Modulation of pain, nociception, and analgesia by the brain reward center.Neuroscience · 2016Review
- RGS6 as a Novel Therapeutic Target in CNS Diseases and Cancer.The AAPS journal · 2016Review
- RGS9-2--controlled adaptations in the striatum determine the onset of action and efficacy of antidepressants in neuropathic pain states.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Differential roles of dopamine D1 and D2 receptors in pain modulation: a review.Frontiers in neurologyReview
- Pain vulnerability and DNA methyltransferase 3a involved in the affective dimension of chronic pain.Molecular painArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
The signal transduction modulator Rgs9-2 (Regulator of G protein signaling 9-2) plays a key role in dopaminergic and opioidergic transmission in the striatum. Rgs9-2 is a potent modulator of opiate reward and analgesia, but its role in chronic pain remains unknown. Here, we use the spared nerve injury model (SNI), to evaluate the influence of Rgs9-2 in sensory symptoms, as well as in anxiety and depression-like behaviors observed under neuropathic pain conditions. Our data demonstrate that knockout of the Rgs9 gene reduces the intensity of thermal hyperalgesia and mechanical allodynia the first few days after nerve injury. This small, but significant effect is only observed at early time points after nerve injury, whereas after the first week of SNI, Rgs9 knockout (Rgs9KO) and Rgs9 wildtype (Rgs9WT) mice show similar levels of mechanical allodynia and thermal hyperalgesia. Furthermore, Rgs9-2 deletion exacerbates anxiety and depression like behaviors several weeks after the emergence of the neuropathic pain symptoms. Our findings also reveal a temporal and regional regulation of Rgs9-2 protein expression by neuropathic pain, as Rgs9-2 levels are reduced in the spinal cord a few days after nerve injury, whereas decreased Rgs9-2 levels in the Nucleus Accumbens (NAc) are only observed several weeks after nerve injury. Thus, adaptations in Rgs9-2 activity in the spinal cord and in the NAc may contribute to sensory and affective components of neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.